License to kill: microsatellite instability and immune contexture

被引:10
作者
Maby, Pauline [1 ,2 ,3 ]
Bindea, Gabriela [1 ,2 ,3 ]
Mlecnik, Bernhard [1 ,2 ,3 ,4 ]
Galon, Jerome [1 ,2 ,3 ]
机构
[1] INSERM, Lab Integrat Canc Immunol, Paris, France
[2] Equipe Labellisee Ligue Canc, Paris, France
[3] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, Paris, France
[4] Inovarion, Paris, France
来源
ONCOIMMUNOLOGY | 2021年 / 10卷 / 01期
关键词
T-cells; microsatellite instability; tumor microenvironment; colorectal cancer; prognosis; survival; immunity; immunoscore; immunotherapy; IMMUNOSCORE; SURVIVAL;
D O I
10.1080/2162402X.2021.1905935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancers (CRCs) with microsatellite instability (MSI) are due to a defect in the DNA mismatch repair (MMR) system resulting in an accumulation of frame-shift mutations. They are characterized by a tumor microenvironment richer in cytotoxic CD8 T-cells (CTLs) and a better prognosis compared to microsatellite stable (MSS) CRCs. The mechanisms by which defective MMR system may influence tumor-infiltrating immune cells and their impact on patient survival were still unclear. Thus, we performed a comprehensive analysis of MSI colorectal tumors. We found that the numbers of frame-shift mutations potentially resulting in neo-epitopes were positively correlated to the density of tumor infiltrating CD8 T-cells but were lower than expected at random. We also evidenced that MSI patients could naturally harbor CTLs targeting frame-shift mutation-derived antigens. This favors the hypothesis of an active immunosurveillance in MSI colorectal tumors leading to the genetic evidence of an immunoediting. To evaluate the link between MSI tumor immune contexture and prognosis, we took advantage of a standardized assay that we developed to quantify tumor-infiltrating T-cells, the Immunoscore. Multivariate analyses revealed an advantage of Immunoscore over MSI in predicting recurrence and survival. Our data suggests that the prognostic value of MSI could be attributed to major underlying differences of infiltrating immune cells. Immunotherapeutic treatments, that are more efficient in patients with a preexisting anti-tumor immunity, were approved in MSI patients following successful clinical trials. We suggest that the Immunoscore could be used not only for colorectal tumor prognosis but also for predicting responses to immunotherapies.
引用
收藏
页数:4
相关论文
共 21 条
  • [1] Trial Watch Peptide vaccines in cancer therapy
    Aranda, Fernando
    Vacchelli, Erika
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Tartour, Eric
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    [J]. ONCOIMMUNOLOGY, 2013, 2 (12): : 1 - 11
  • [2] The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
    Bindea, Gabriela
    Mlecnik, Bernhard
    Fridman, Wolf-Herman
    Galon, Jerome
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2011, 33 (04) : 335 - 340
  • [3] The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
    Bruni, Daniela
    Angell, Helen K.
    Galon, Jerome
    [J]. NATURE REVIEWS CANCER, 2020, 20 (11) : 662 - 680
  • [4] Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
    Buque, Aitziber
    Bloy, Norma
    Aranda, Fernando
    Castoldi, Francesca
    Eggermont, Alexander
    Cremer, Isabelle
    Fridman, Wolf Herve
    Fucikova, Jitka
    Galon, Jerome
    Marabelle, Aurelien
    Spisek, Radek
    Tartour, Eric
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    [J]. ONCOIMMUNOLOGY, 2015, 4 (04):
  • [5] Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
    Galon, J.
    Fox, B. A.
    Bifulco, C. B.
    Masucci, G.
    Rau, T.
    Botti, G.
    Marincola, F. M.
    Ciliberto, G.
    Pages, F.
    Ascierto, P. A.
    Capone, M.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [6] Tumor Immunology and Tumor Evolution: Intertwined Histories
    Galon, Jerome
    Bruni, Daniela
    [J]. IMMUNITY, 2020, 52 (01) : 55 - 81
  • [7] Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
    Galon, Jerome
    Bruni, Daniela
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 197 - 218
  • [8] Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
    Kirilovsky, Amos
    Marliot, Florence
    El Sissy, Carine
    Haicheur, Nacilla
    Galon, Jerome
    Pages, Franck
    [J]. INTERNATIONAL IMMUNOLOGY, 2016, 28 (08) : 373 - 382
  • [9] Frameshift mutations, neoantigens and tumor-specific CD8+ T cells in microsatellite unstable colorectal cancers
    Maby, Pauline
    Galon, Jerome
    Latouche, Jean-Baptiste
    [J]. ONCOIMMUNOLOGY, 2016, 5 (05):
  • [10] Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy
    Maby, Pauline
    Tougeron, David
    Hamieh, Mohamad
    Mlecnik, Bernhard
    Kora, Hafid
    Bindea, Gabriela
    Angell, Helen K.
    Fredriksen, Tessa
    Elie, Nicolas
    Fauquembergue, Emilie
    Drouet, Aurelie
    Leprince, Jerome
    Benichou, Jacques
    Mauillon, Jacques
    Le Pessot, Florence
    Sesbouee, Richard
    Tuech, Jean-Jacques
    Sabourin, Jean-Christophe
    Michel, Pierre
    Frebourg, Thierry
    Galon, Jerome
    Latouche, Jean-Baptiste
    [J]. CANCER RESEARCH, 2015, 75 (17) : 3446 - 3455